Risankizumab Versus Placebo in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment in the Russian Federation (IMMpress)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 May 2019
Price : $35 *
At a glance
- Drugs Risankizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IMMPRESS
- Sponsors AbbVie
- 24 May 2019 Planned End Date changed from 9 Dec 2019 to 5 Feb 2020.
- 21 Dec 2018 Planned End Date changed from 7 Feb 2020 to 9 Dec 2019.
- 21 Dec 2018 Status changed from recruiting to active, no longer recruiting.